UK-based licensed cultivator, Glass Pharms, has announced a new partnership with Mamedica Clinic to supply cannabis flower for their own line of medicinal products. This move marks a significant step towards a fully domestic supply chain for medical cannabis in the UK.
Glass Pharms has been steadily growing a variety of medical cannabis flowers for the production of CBPMs (Cannabis Based Products for Medicinal Use). Their range now includes fourteen different cultivars, each with its own unique combination of cannabinoids and terpene profiles. Notably, their THC:CBD Balanced cultivar has achieved the demanding 5.1.4 microbial standard without the use of irradiation.
The high quality of Glass Pharms’ products has led to widespread adoption by physicians across a variety of UK clinics, including Mamedica, Releaf, Curaleaf, Integro, CB1, Lyphe, and Therismos.
Mamedica, in particular, has been prescribing several products derived from Glass Pharms’ flower this year and has determined that the consistent quality of their products makes them suitable for use as a standardised part of their formulary.
“We are really happy to be supporting UK cultivation and the quality of this product meets the exacting standards our patients expect,” said Jon Robson, CEO and founder of Mamedica.
Glass Pharms’ CEO, James Duckenfield, also expressed his excitement about the new partnership, stating, “Expanding the range of cannabis flower choices for prescribing options to meet all clinical needs is important to Glass Pharms and we are happy to announce this new partnership with Mamedica.”
Both Robson and Duckenfield will be speaking at the upcoming Cannabis Europa event on June 25th, where they will be discussing the topic of “Domestic vs Import: Does it Really Matter for Medical Cannabis Supply”. Additionally, Glass Pharms has been short-listed for “Producer of the Year” at the Business of Cannabis Awards, which will take place on June 24th.
For more information about Glass Pharms and their products, please visit their website at https://glasspharms.com/.
Derick is an experienced reporter having held multiple senior roles for large publishers across Europe. Specialist subjects include small business and financial emerging markets.